Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Liron Caplan, MD PhD
Rocky Mountain Regional VA Medical Center, Aurora, CO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Va Caribbean Healthcare System, San Juan, Pr
San Juan, Puerto Rico
- San Francisco Va Medical Center, San Francisco, Ca
San Francisco, California, United States
- Rocky Mountain Regional Va Medical Center, Aurora, Co
Aurora, Colorado, United States
- Baltimore Va Medical Center Va Maryland Health Care System, Baltimore, Md
Baltimore, Maryland, United States
- Durham Va Medical Center, Durham, Nc
Durham, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Oct 2016
- Primary completion
- 31 Dec 2019
- Completion
- 28 Feb 2025
- Last update posted
- 27 May 2026
- Registered enrollment
- 5,269
- Registry id
- NCT02694185
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.